Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

ADDEX THERAPEUTICS LTD

(ADXN)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur ADDEX THERAPEUTICS LTD
18/11Addex to Present at the Virtual German Equity Forum
15/11ADDEX THERAPEUTICS : Setting Up Global Expansion of Phase 2 Clinical Evaluation in Epileps..
15/11Addex-Partner Janssen bringt Epilepsie-Kandidaten ADX71149 in Phase-II-Studie
15/11Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149
15/11Addex to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
04/11INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K
04/11Addex Therapeutics Ltd Reports Earnings Results for the Third Quarter and Nine Months E..
04/11Addex weitet wegen gestiegener Kosten Verluste leicht aus
04/11Addex Reports Q3 2021 Financial Results and Provides Corporate Update
01/11Addex Therapeutics to Release Q3 2021 Financial Results and Host Conference Call on Nov..
06/10Addex to Present at the Investors' Day hosted by Voxia Communication
06/10ADDEX THERAPEUTICS : Addex to Present at the Investors' Day hosted by Voxia Communication
06/10ADDEX THERAPEUTICS : to Present at the Investors' Day hosted by Voxia Communication
04/10Addex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors
29/09ADDEX THERAPEUTICS : Type of dystonia characterized by involuntary spasms of the eyelid mu..
29/09ADDEX THERAPEUTICS : Commences Mid-Stage Trial of Dipraglurant in Blepharospasm
29/09Addex startet Phase-II-Studie mit Dipraglurant zur Behandlung von Lidkrampf
29/09ADDEX THERAPEUTICS : Starts Mid-Stage Trial For Eyelid Muscles Spasm Drug
29/09Addex Therapeutics Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm
29/09Addex to Present at the Cantor Global Healthcare 2021 Conference
29/09Addex Therapeutics Ltd Initiates Phase 2 Clinical Study with Dipraglurant in Blepharosp..
22/09ADDEX THERAPEUTICS : CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM..
22/09ADDEX THERAPEUTICS : Charcot-Marie-Tooth Association Team Up to Study Potential of Muscle ..
22/09Addex und Charcot-Marie-Tooth Association kündigen Forschungszusammenarbeit an
22/09ADDEX THERAPEUTICS : CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM..
22/09CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM as Potential Trea..
22/09The Charcot–Marie–Tooth Association and Addex Therapeutics Enter Collaboration to Advan..
08/09ADDEX THERAPEUTICS : to Present at the H.C. Wainwright 23rd Annual Global Investment Confe..
02/09Addex to Present at the Swiss Biotech Day
05/08ADDEX THERAPEUTICS : INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENT..
05/08Addex rutscht wegen höherer Kosten im zweiten Quartal tiefer ins Minus
05/08Addex Therapeutics Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2..
05/08ADDEX THERAPEUTICS : Half Year Report
05/08ADDEX THERAPEUTICS : to Present at the Baader Helvea Swiss Equities Conference
05/08ADDEX THERAPEUTICS : to Ring the Nasdaq Stock Market Closing Bell
05/08Addex Reports 2021 Half Year and Second Quarter Financial Results and Provides Corporat..
02/08ADDEX THERAPEUTICS : Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head o..
02/08Addex ernennt Mikhail Kalinichev zum Leiter Translational Science
02/08ADDEX THERAPEUTICS : to Release Half-Year 2021 Financial Results and Host Conference Call ..
02/08Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translatio..
02/08Addex Therapeutics Ltd Appoints Mikhail Kalinichev as Head of Translational Science
29/07ADDEX THERAPEUTICS : and Indivior Extend Research Collaboration on GABAB Positive Alloster..
29/07Addex erhält von Partner Indivior im Zuge verlängerter Zusammenarbeit 4 Mio USD
29/07ADDEX THERAPEUTICS : and Indivior Extend Research Collaboration on GABAB Positive Alloster..
29/07Addex Therapeutics and Indivior Extend Research Collaboration on Gabab Positive Alloste..
29/07Addex Therapeutics Ltd announced that it expects to receive $4 million in funding from ..
23/07ADDEX THERAPEUTICS : to Present at the 20th Annual Needham Virtual Healthcare Conference
23/07ADDEX THERAPEUTICS : to Present at Access to Giving Virtual Conference on July 14, 2021
23/07ADDEX THERAPEUTICS : to Present at the H.C. Wainwright Global Life Sciences Conference
07/07Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021
07/07Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021
01/07ADDEX THERAPEUTICS : Stanford University and University of Copenhagen Publish mGlu2 Struct..
01/07Addex veröffentlicht Studienergebnisse in Fachpublikation
01/07ADDEX THERAPEUTICS : Stanford University and University of Copenhagen Publish mGlu2 Struct..
30/06ADDEX THERAPEUTICS : INCORPORATION BY REFERENCE (Form 6-K)
30/06ADDEX THERAPEUTICS : Enters Into At-The-Market ADS Offering Program With Cantor Fitzgerald
30/06ADDEX THERAPEUTICS : to Offer American Depositary Shares via At-The-Market Program
30/06Addex lanciert ADS-Programm an der Nasdaq
30/06Addex Establishes At-The-Market ADS Equity Sale Program
29/06ADDEX THERAPEUTICS : Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia A..
29/06ADDEX THERAPEUTICS : Starts Phase 2b/3 Trial of Dipraglurant in Dyskinesia Associated With..
29/06ADDEX THERAPEUTICS : Initiates Clinical Trial For Dipraglurant In Parkinson's Patients
29/06ADDEX THERAPEUTICS : Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia A..
29/06Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia ..
29/06Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia ..
29/06Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia ..
28/06Addex startet zulassungsrelevante Studie mit Dipraglurant bei Parkinson
17/06ADDEX THERAPEUTICS : Shareholders Approve All Resolutions at Annual General Meeting (Form ..
17/06Addex Shareholders Approve All Resolutions at Annual General Meeting
07/06ADDEX THERAPEUTICS : Commences Enrollment in Phase 2 Trial of Epilepsy Drug
07/06ADDEX THERAPEUTICS : First patients enrolled into multi-center U.S. study (Form 6-K)
07/06ADDEX THERAPEUTICS : Enrolls First Patient in Mid-Stage Study of Epilepsy Drug
07/06Addex-Partner Janssen rekrutiert ersten Patienten für Epilepsie-Studie
07/06Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
07/06Addex Therapeutics Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
1  2  3  4  5  6  7Suiv.
Prochain événement sur ADDEX THERAPEUTICS LTD